Brief: Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata
30/04/2025 12:17
April 30 (Reuters) - Q32 Bio Inc QTTB.O: Q32 BIO ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO BEMPIKIBART (ADX-914) FOR THE TREATMENT OF ALOPECIA AREATA Source text: ID:nPn2rFZ1ta Further company coverage: QTTB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview